Literature DB >> 15633214

Survivin antisense compound inhibits proliferation and promotes apoptosis in liver cancer cells.

De-Jian Dai1, Cai-De Lu, Ri-Yong Lai, Jun-Ming Guo, Hua Meng, Wei-Sheng Chen, Jun Gu.   

Abstract

AIM: To evaluate the effects of survivin on cell proliferation and apoptosis in liver cancer.
METHODS: MTT assay was used to generate and optimize phosphorothioate antisense oligonucleotides (ODNs)-Lipofectamine2000 (LiP) compound by varying ODNs (mug):LiP (muL) ratios from 1:0.5 to 1:5. Then, liver cancer cells (HepG2) were transfected with the compound. By using RT-PCR and Western blot, the expression levels of survivin mRNA and proteins were detected in HepG2 cells treated with antisense compounds (ODNs:LiP = 1:4), and compared with those treated with sense compounds (1:4) as control. MTT assay was applied to the determination of cell proliferation in HepG2 cells. Active caspase-3 was evaluated by flow cytometric analysis. The morphological changes were assessed by electron microscopy. Laser scanning confocal microscopy was performed to detect the subcellular localization of survivin proteins in treated and untreated cells.
RESULTS: Antisense compounds (1:4) down-regulated survivin expression (mRNA and protein) in a dose-dependent manner with an IC50 of 250 nmol/L. Its maximum effect was achieved at a concentration of 500 nmol/L, at which mRNA and protein levels were down-regulated by 80%. The similar results were found in MTT assay. Antisense compound (1:4)-treated cells revealed increased caspase-3-like protease activity compared with untreated cells. Untreated cells as control were primarily negative for the presence of active-caspase-3. As shown by transmission electron microscopy, treated cells with antisense compounds (1:4) resulted in morphological changes such as blebbing and loss of microvilli, vacuolization in the cytoplasm, condensation of the cytoplasm and nuclei, and fragmented chromatin. Immunofluorescence analysis confirmed the presence of survivin protein pool inside the cytoplasm in untreated cells. Labeled-FITC immunofluorescence staining of survivin clearly showed that survivin was distributed mainly in a spotted form inside the cytoplasm. Whereas cells treated with antisense compounds were rare and weak inside the cytoplasm.
CONCLUSION: Down-regulation of survivin expression induced by the antisense compounds reduces tumor growth potential, promotes apoptosis and affects the localization of survivin proteins in HepG2 cells. Furthermore, survivin protein is a key molecule associated with proliferation and apoptosis, and antisense oligonucleotides targeting survivin have a bright prospect in the therapy of liver cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15633214      PMCID: PMC4205400          DOI: 10.3748/wjg.v11.i2.193

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosis.

Authors:  S P Wheatley; A Carvalho; P Vagnarelli; W C Earnshaw
Journal:  Curr Biol       Date:  2001-06-05       Impact factor: 10.834

Review 2.  IAP family proteins--suppressors of apoptosis.

Authors:  Q L Deveraux; J C Reed
Journal:  Genes Dev       Date:  1999-02-01       Impact factor: 11.361

3.  A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy.

Authors:  R A Olie; A P Simões-Wüst; B Baumann; S H Leech; D Fabbro; R A Stahel; U Zangemeister-Wittke
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

Review 4.  Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities.

Authors:  A Nakagawara
Journal:  Hum Cell       Date:  1998-09       Impact factor: 4.174

5.  Survivin promotes cell proliferation in human hepatocellular carcinoma.

Authors:  T Ito; K Shiraki; K Sugimoto; T Yamanaka; K Fujikawa; M Ito; K Takase; M Moriyama; H Kawano; M Hayashida; T Nakano; A Suzuki
Journal:  Hepatology       Date:  2000-05       Impact factor: 17.425

6.  Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins.

Authors:  A M Verhagen; P G Ekert; M Pakusch; J Silke; L M Connolly; G E Reid; R L Moritz; R J Simpson; D L Vaux
Journal:  Cell       Date:  2000-07-07       Impact factor: 41.582

Review 7.  Apoptosis and cancer chemotherapy.

Authors:  G Makin; J A Hickman
Journal:  Cell Tissue Res       Date:  2000-07       Impact factor: 5.249

8.  Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation.

Authors:  C Adida; P L Crotty; J McGrath; D Berrebi; J Diebold; D C Altieri
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

9.  IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs.

Authors:  I Tamm; Y Wang; E Sausville; D A Scudiero; N Vigna; T Oltersdorf; J C Reed
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

Review 10.  The inhibitors of apoptosis (IAPs) and their emerging role in cancer.

Authors:  E C LaCasse; S Baird; R G Korneluk; A E MacKenzie
Journal:  Oncogene       Date:  1998-12-24       Impact factor: 9.867

View more
  6 in total

1.  Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma.

Authors:  Chao-Ping Ye; Cheng-Zhi Qiu; Zhong-Xin Huang; Qi-Chen Su; Wei Zhuang; Rui-Lan Wu; Xin-Feng Li
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

2.  Sequestering survivin to functionalized nanoparticles: a strategy to enhance apoptosis in cancer cells.

Authors:  Ragini Jenkins; Yuriy P Bandera; Michael A Daniele; LeAnna L Ledford; Ashlee Tietje; Andrew A Kelso; Michael G Sehorn; Yanzhang Wei; Mrinmay Chakrabarti; Swapan K Ray; Stephen H Foulger
Journal:  Biomater Sci       Date:  2016-02-04       Impact factor: 6.843

3.  Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.

Authors:  Nicolas Charette; Christine De Saeger; Valérie Lannoy; Yves Horsmans; Isabelle Leclercq; Peter Stärkel
Journal:  Mol Cancer       Date:  2010-09-22       Impact factor: 27.401

4.  Downregulation of B7-H4 suppresses tumor progression of hepatocellular carcinoma.

Authors:  Lijie Dong; Lulu Xie; Minjing Li; Hanhan Dai; Xia Wang; Peiyuan Wang; Qiang Zhang; Wei Liu; Xuemei Hu; Mingdong Zhao
Journal:  Sci Rep       Date:  2019-10-16       Impact factor: 4.379

5.  Effects of matrine in combination with cisplatin on liver cancer.

Authors:  Gaoyu Hu; Cong Cao; Zhihua Deng; Jun Li; Xihan Zhou; Zansong Huang; Chao Cen
Journal:  Oncol Lett       Date:  2020-11-25       Impact factor: 2.967

6.  Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms.

Authors:  N Charette; C De Saeger; Y Horsmans; I Leclercq; P Stärkel
Journal:  Cell Death Dis       Date:  2013-01-24       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.